RAD51 Inhibitors Enhance Potency and Selectivity for Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current RAD51 inhibitors, such as IBR2, have limited potency with IC50 values in the range of 12-20 μM for most cancer cell lines, necessitating the development of more effective compounds to target RAD51 for treating cancers like triple-negative breast cancer.
Innovation Solution
Development of novel RAD51 inhibitors represented by compounds IBR101-124, which include specific chemical structures and formulations that enhance RAD51 inhibition, with IBR120 demonstrating a 4.8-fold improved growth inhibition activity in triple-negative breast cancer cells and a 10-fold difference in IC50 values between normal and cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current RAD51 inhibitors (IBR2) are used, then RAD51 inhibition is achieved, but potency is limited with IC50 values in the range of 12-20 μM
Solution Approach 1:
The patent modifies the chemical structure of IBR2 by changing parameters such as the heteroaryl ring type (Het), substituent groups (R1-R29), and molecular configuration to develop compounds with improved potency. Specifically, compounds IBR101-124 were designed with variations in the core isoindolinone structure, including different heteroaryl groups (indolyl, azaindolyl, thiazolyl) and substituent patterns, resulting in IC50 values as low as 0.2-2.0 μM, representing a 6-10 fold improvement over IBR2
Solution Approach 2:
The patent creates composite molecular structures by combining the isoindolinone core with various heteroaryl rings and substituent groups. This composite approach allows optimization of both RAD51 binding affinity and selectivity, producing compounds that maintain the mechanism of action of IBR2 while achieving significantly improved potency through structural complexity and molecular diversity
2Reliability
If RAD51 inhibition is enhanced to treat cancer, then therapeutic efficacy is improved, but selectivity between cancer and normal cells must be maintained
Solution Approach 1:
The patent exploits local quality differences between cancer and normal cells by targeting RAD51, which is overexpressed in cancer cells but present at lower levels in normal cells. The compounds IBR101-124 were demonstrated to have selective toxicity toward cancer cells with IC50 values 5-10 fold lower in cancer cell lines compared to normal fibroblasts, achieving therapeutic window through differential expression targeting
Solution Approach 2:
Instead of attempting to protect normal cells from RAD51 inhibition, the patent inverts the approach by selectively enhancing RAD51 inhibition in cancer cells where RAD51 is overexpressed. The compounds are designed to exploit the elevated RAD51 levels in cancer as a vulnerability, turning the cancer cells' reliance on RAD51 for DNA repair into a therapeutic opportunity through selective compound-cancer cell interaction
Data Source
AI summary
The present invention includes novel RAD51 inhibitors. The compounds of the invention may be useful in preventing or treating cancer in a subject in need thereof. The present invention also includes methods of preventing or treating cancer in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of the invention.